ReachMD CME ReachMD

CME credits: 0.25
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/



There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.
=

CME credits: 0.50
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/



GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities.
=

CME credits: 0.25
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/making-the-case-for-dual-ang-2-vegf-a-inhibition-durability-and-drying/18008/



What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.
=

CME credits: 1.00
Valid until: 02-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/get-real-a-guide-to-evolving-treatment-of-namd-and-dme-using-real-world-data/16619/



Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.
=

CME credits: 0.25
Valid until: 16-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/south-asians-with-ibd-underrepresented-and-underappreciated/18122/



A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.
=

CME credits: 0.25
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/applying-sdm-to-personalize-treatment-discussions-on-recurrence-risk-reduction-in-patients-with-early-stage-melanoma/18105/



This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting.
=